Baxter price target raised to $23 from $22 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Baxter (BAX) to $23 from $22 and keeps a Neutral rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note.